All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The Multiple Myeloma Hub was pleased to speak to Naresh Bumma, The Ohio State University, Columbus, US. We asked, How does linvoseltamab differ from other bispecific antibodies?
How does linvoseltamab differ from other bispecific antibodies?
In this video interview, Naresh Bumma opens by discussing the latest approvals and developments in bispecific antibodies for the treatment of multiple myeloma. He goes on to present key efficacy and safety data from LINKER-MM1 trial (NCT03761108), highlighting the outcomes observed with linvoseltamab compared with data of alternative bispecific antibodies.
Bumma notes the similarity in response rates across the same drug class but highlights infection, neurotoxicity, ICANS and CRS rates as differentiators favoring linvoseltamab over existing bispecific antibodies.
Subscribe to get the best content related to multiple myeloma delivered to your inbox